Clinical Trials Browser

Phase 1 × Temozolomide × Endocrine × Clear all

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT01076530 2013-05-03

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Phase 1 Completed

27 enrolled

CNSEndocrine

Familial ependymoma, Astrocytoma, Medulloblastoma, Oligodendroglioma, Paraganglioma, Extra-Adrenal, Spinal Cord Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor, Optic Nerve Glioma

Clinical Trials

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors